The window for preventing permanent lung damage in cystic fibrosis may be narrower than clinicians realized. While current treatments focus on school-age children showing obvious symptoms, inflammatory processes that drive lifelong complications appear to begin in preschoolers before structural damage becomes apparent.
Single-cell analysis of lung samples from 45 children revealed widespread dysfunction in macrophages—immune cells responsible for clearing infections and maintaining tissue health. These cellular sentinels showed disrupted TNF and interferon signaling pathways, altered cholesterol metabolism, and activated fibrosis programs even in very young patients. The dysfunction intensified as early bronchiectasis developed, suggesting a cascading inflammatory process that becomes increasingly difficult to reverse.
The precision medicine drug ivacaftor partially restored normal macrophage function and reduced signals that recruit neutrophils to inflamed airways. However, the combination therapy lumacaftor/ivacaftor showed no detectable benefit, highlighting how different CFTR modulators produce distinct cellular responses despite targeting the same defective protein.
This finding challenges the current paradigm of waiting for symptoms before intervening aggressively. The comprehensive cellular atlas—spanning 190,000 cells across 43 distinct lung cell types—reveals that inflammatory programming begins much earlier than previously documented. For the 30,000 Americans living with cystic fibrosis, this suggests anti-inflammatory treatments may need to start in toddlerhood rather than adolescence to prevent the chronic lung infections and tissue scarring that define the disease's progression. The work provides a molecular roadmap for developing targeted therapies that could interrupt inflammation before permanent damage occurs.